Abstract: Monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein (MIP-1 ) are implicated in monocyte infiltration into the central nervous system (CNS) under pathological conditions. We previously showed that in vivo human umbilical cord blood cells (HUCB) migrate toward brain injury after middle cerebral artery occlusion (MCAO). We hypothesized that MCP-1 and MIP-1 may participate in the recruitment of HUCB towards the injury. Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO), and 24 hours later the production of MCP-1 and MIP-1 in the brain was examined with immunohistochemistry, ELISA, and western blotting. The chemotactic effect of MCP-1 and MIP-1 , and the expression of MCP-1 receptor CCR2 and MIP-1 receptor CCR1, CCR5 on the surface of HUCB were also examined. MCP-1 and MIP-1 expression were significantly increased in the ischemic hemisphere of brain, and significantly promoted HUCB cell migration compared to the contralateral side. This cell migration was neutralized with polyclonal antibodies against MCP-1 or MIP-1 . Also chemokine receptors were constitutively expressed on the surface of HUCB cells. The data suggested that the increased chemokines in the ischemic area can bind cell surface receptors on HUCB, and induce cell infiltration of systemically delivered HUCB cells into the CNS in vivo.
INTRODUCTION
Intravenous delivery of human umbilical cord blood cells (HUCB) decreases neural damage in rodents subjected to middle cerebral artery occlusion (MCAO) , and provides better behavioral and neurological recovery in a rodent model of stroke compared to direct intracranial delivery (Willing et al., 2003) . While an additional advantage of the systemic route is the ease of delivery, how these cells migrate into the brain to produce their effects is not clear, since the brain is insulated by the blood brain barrier (BBB) and has immune privilege. One possibility is that BBB is disrupted after the ischemic insult and granulocytes, macrophages, and other inflammatory cells leak into the ischemic brain passively. A second possibility is that stroke up-regulated chemoattractants, which promote HUCB cell migration into the brain. One of the potential chemoattractants is monocyte chemoattractant protein-1 (MCP-1). MCP-1 has been detected in injured brain after stroke (Babock et al., 2003) , predominantly in astrocytes (Che et al., 2001) . Other studies found that hypoxia-ischemia increases MCP-1 expression in multiple cell types around the site of injury in neonatal rodent *Address correspondence to this author at the Center of Excellence for Aging & Brain Repair, MDC78, University of South Florida, 12901 Bruce B. Downs Blvd, Tampa FL 33612, USA; Received: December 27, 07, Revised: April 2, 08, Accepted: April 4, 08 brain (Ivacko et al., 1997) . Following MCP-1 expression, leukocytes could be found in the lesioned hippocampus. In addition, mutant mice with a CCR2 (MCP-1 receptor) deficit had neither T cells nor macrophage infiltration in the denervated hippocampus, suggesting a critical role for MCP-1 and its receptor CCR2 in leukocyte migration (Babock et al., 2003) .
Another potential chemoattractant implicated in the trafficking of lymphoid and mononuclear cell into the CNS is macrophage inflammatory protein (MIP-1 ). It is up regulated as early as 3 to 6 hr post stroke in the ipsilateral hemisphere to the stroke, whereas the level of MIP-1 in the contralateral hemisphere was similar to control levels (Kim et al., 1995a; Takami et al., 1997) . MIP-1 mRNA was also found present in an immortalized microglia cell line, cortical astrocytes and monocytes in culture (Murphy et al., 1995) . In vivo, MIP-1 expression was correlated with mononuclear cell infiltration (Glabinski et al., 1998) . Further, extracts from ischemic brain induced human bone marrow stromal cell migration in culture, and this cell migration could be blocked by an MIP-1 antibody, suggesting a chemoattractant effect of MIP-1 (Wang et al., 2002) .
In this study we examined whether MIP-1 and MCP-1 expression increased in the damaged hemisphere after stroke and if the presence of these chemokines in extracts of stroke brain would induce HUCB migration in an ex vivo assay system.
MATERIALS AND METHODS

Middle Cerebral Artery Occlusion (MCAO)
Twenty Sprague Dawley rats were randomly assigned to the MCAO or normal groups as previously described (Willing et al., 2003) . Briefly, animals were anesthetized with isoflurane (2-5% in 2 L/min O 2 ). The right common, external and internal carotid arteries were isolated and an embolus inserted retrogradely through the external carotid, into the internal carotid, past the base of the skull to the origin of the MCA (approximately 25mm from insertion). The filament was permanently anchored in place and the incision closed. All animals were euthanized 24h post surgery, and the brains were harvested. Some of the brains were fixed with 4% paraformaldehyde in PBS, and the others were immediately frozen in liquid nitrogen.
Neural Cell Hypoxia Culture
Neurons, astrocytes and microglia were isolated from fetal rat brain at embryonic day (E) 17 as described (Mackay, 2001; Rothenberg et al., 1999) , and grown separately in culture to confluency. Before hypoxia, the gas-tight chamber (Hornung et al., 2000; Wang et al., 2002) was flushed with 5% CO 2 and 95% N 2 and the plates washed with low glucose color free DMEM medium. For the hypoxia group, medium was changed to 1 ml hypoxia pre-treated, low glucose, color free DMEM and cultures placed in the gas-tight chamber. The cultures were exposed to hypoxia (5% CO 2 and 95%N 2 ) at 37 o C for 2 hours (Lombardi et al., 2003) . The control group was treated with low glucose color free DMEM under normoxic conditions for 2 hour. The media were harvested, and cells prepared for western blotting.
Immunohistochemistry Staining
MIP-1 (or MCP-1) Double Labeling
The fixed brains were sectioned on a cryostat at 30 m thick. The sections were blocked with 10% goat serum, 0.3% Triton X100 in PBS for 1 hour, and then incubated with primary antibody cocktail at 4 o C overnight. The cocktail consisted of goat anti MIP-1 (Santa Cruz; 1:100) or rabbit anti MCP-1 (Novus; 1:100) with either mouse anti OX-42 (CD11b/c) (Abcam; 1:100), mouse anti TuJ1 (Chemicon; 1:400) or chicken anti GFAP (Chemicon; 1:100). After washing, the sections were incubated with a secondary antibody cocktail of rhodamine-conjugated goat anti-rabbit IgG (Molecular Probes; 1:500) and FITC-conjugated goat antimouse IgG (Molecular Probes; 1:500). The sections were mounted and examined with a confocal microscope.
Chemokine Receptor Immunolabeling
HUCB smears were fixed with 4% paraformaldehyde, washed and then air dried. The slides were stained with primary and secondary antibody as described above. The primary antibodies used were goat anti-human CCR5 (Capralogics Inc, 1:200), rabbit anti-human CCR1, and mouse anti-human CCR2 (Abcam Inc, 1:200) . Secondary antibodies were FITC-conjugated goat anti-mouse IgG or rhodamineconjugated goat anti-rabbit IgG (Molecular Probes; 1:500) (Molecular Probes; 1:500).
Western Blotting
The brains were cut sagitally into stroke side (ipsilateral to MCAO) and non-stroke side (contralateral to MCAO) and the tissue lysed. An equivalent amount of protein was loaded on SDS-12% polyacrylamide gel and transferred to nitrocellulose paper. The membranes were immunoblotted with antirat MIP-1 (Chemicon) followed by horseradish peroxidaseconjugated secondary antibody. After the final wash, membranes were probed using enhanced chemiluminescence dye (ECL, Amersham Pharmacia Biotech, Piscataway, NJ) and autoradiographed. Neural cells from culture were treated similarly.
MCP-1 ELISA Assay
The brains were cut sagitally into stroked side and nonstroked side. Tissues were weighed, placed in clear DMEM (Gibco, 150mg/ml), homogenized and centrifuged at 2000g for 20 minutes. The supernatants were collected, filtered and adjusted to the same protein concentration. The ELISA assay was performed according to manufacturer's protocol (Amersham Bioscience), and the concentration of chemokine was determined on a plate reader at absorbance of 450nm and 550nm.
Cell Migration Assay
The standard (chemokine protein) or tissue extract samples (300 L) with or without MCP-1 or MIP-1 antibodies (1:100) were pipetted into the bottom wells of a 96-well plate. Freshly thawed HUCB cells were directly pipetted into the top well at a concentration of 100,000 cells per 60 L. The migration chamber was incubated at 37 o C with 5% CO 2 from 4 hours to 24 hours. The top well plate was then removed and the bottom plate was centrifuged, and 200 l media removed. The number of migrated cells was determined with Cell Titer-Glo Luminescent Cell Viability Assay, (Promega) according to the manufacturer's protocol. The plate was read in a plate reader. The migration assays were performed twice. Each sample, control and standard was performed in triplicate.
RESULTS
Presence of MIP-1 and MCP-1 in the Stroked Brain
Both MCP-1 and MIP-1 were found in the brain 24 hour after MCAO using immunolabeling. No positive staining was found in the contralateral hemisphere. Double immunochemistry staining revealed that both MCP-1 and MIP-1 were found in neurons (Fig. (1) ), astrocytes (Fig. (2) ), and some microglia (Fig. (3) ). MIP-1 expression was verified with western blotting (Fig. (4A) ) from extracts of stroked brain. Further, in enriched cultures, MIP-1 was expressed in cultured astrocytes and neurons. After hypoxia, MIP-1 increased in neurons compared to neurons only exposed to normoxia conditions (Fig. (4B) ). MCP-1 expression was verified with ELISA. It was significantly increased on the stroked side of the brain compared to the contralateral side after stroke (p<0.05) (Fig. (5A) ). In enriched cultures, hypoxia induced MCP-1 expression particularly in microglia and astrocytes (p<0.05) (Fig. (5B) ). 
Chemotactic Effect of MCP-1 and MIP-1 on HUCB Cell Migration
MIP-1 receptor CCR1 and CCR5 as well as MCP-1 receptor CCR2 were all expressed on the cell surface of HUCB cells (Fig. (6) ) suggesting that HUCB cells could respond to expression of these chemokines. Indeed, MIP-1 induced migration in vitro, especially at the lowest dose, 30 ng/ml (p<0.05; Fig. (7A) ). HUCB cell migration to MCP-1 reached its maximum at a concentration 600 ng/ml although this was not significantly different from the lower doses. In contrast, the 400 ng/ml concentration was significantly different from the 30 ng/ml, 50 ng/ml and 100 ng/ml doses, respectively (* p<0.05; Fig. (7B) ).
Effect of Brain Tissue Extract on HUCB Cell Migration
Tissue extract from the stroked brain induced more HUCB cells to migrate across a membrane than extract of the non-stroked side did (p<0.05; Fig. (8A & 8B) ). Antibodies to both MIP-1 (Fig. (8A) ) and MCP-1 (Fig. (8B) ) antibody depressed migration toward non-stroked values (p<0.05).
DISCUSSION
MIP-1 was observed on the ipsilateral injured side of the brain 24 hours after MCAO as determined with immunohistochemistry and western blotting. Our results are consistent with previous studies that reported MIP-1 expression as early as 1 hour after onset of the MCAO and which peaked at 4-6 hour post surgery in the injured hemispheres (Takami et al., 1997; Kim et al., 1995) . MIP-1 has also been found to increase after other brain injuries such as ischemia (Takami et al., 1997) , stab wound (Ghirnikar et al., 1996) , hypoxia, olfactory target ablation (Thomas et al., 2002) .
The majority of MIP-1 in the body is produced by circulating monocytes. In the CNS, the inducible MIP-1 could exist in astrocytes, microglia, endothelial cells or neurons. Controversy exists, with some groups finding MIP-1 in the astrocytes (Kim et al., 1995b; Miyamoto and Kim, 1999) while others report that it is only produced by Mac-1 mRNA-positive cells including microglia /macrophages (Takami et al., 1997) . Babcock et al. (2003) observed that the MIP-1 was expressed by glial cells and could direct leukocytes to the CNS after axonal injury (Che et al., 2001) . Other investigators indicated MIP-1 was expressed by neuronal cells in culture (Miyamoto and Kim, 1999 ). Immunostaining shows that MIP-1 can be in all three neural cells, but western blotting shows MIP-1 was mainly produced by astrocytes and neurons. The inconsistency between these studies most likely reflects differences between animal models and cell culture techniques.
Similar to MIP-1 , MCP-1 was also found in the ischemic brain around the infarct. ELISA assay revealed that the amount of MCP-1 on the stroked side was 7 fold greater than the contralateral side. MCP-1 was produced by neurons, astrocytes and microglial cells. This is consistent with previous work showing that MCP-1 was detected as early as 3 to 6 hr post stroke in the ipsilateral hemisphere (Babock et al., 2003) and peaked at 2 -3 days post MCAO (Che et al., 2001) . When we examined cultures enriched for neurons, astrocytes or microglia, MCP-1 was mainly expressed in microglia and astrocytes after hypoxia. Using immunochemistry double staining, Che et al. (2001) found the majority of MCP-1 positive cells were astrocytes. This is consistent with work in the cortico-striatal slice (Noraberg et al., 1999) .
However, what leads to MCP-1 and MIP-1 upregulation after stroke is not known. Recent studies revealed that the production of MCP-1 and MIP-1 was regulated by pro-and anti -inflammatory cytokines induced by the ischemic insult. Fig. (7) . Chemokines dose dependently induced HUCB cell migration. (A) MIP-1 at a dose of 30 ng/ml produced optimal HUCB migration after 12 hour incubation, compared to all other MIP-1 concentrations. (B) HUCB cell migration reached its maximum at a concentration of 600 ng/ml. The 400 ng/ml concentration was significantly different from the 30 ng/ml, 50 ng/ml and 100 ng/ml doses, respectively (* p<0.05). (Minami et al., 1991) ; following that, MCP-1 and MIP-1 production increased. Further, dexamethasone and IL-10 (both anti-inflammatory) significantly reduced MCP-1 expression. However, in knockout mice where interleukin-1 converting enzyme (ICE), a cysteine protease that cleaves inactive pro-IL-1 to generate mature IL-1 , was removed, MCP-1 expression was similar to wild type animals when animals underwent severe hypoxia. With a less severe hypoxic incident, ICE-/-did attenuate MCP-1 expression compared to wild type animals (Xu et al., 2001) . The inductive MCP-1 expression is regulated by ligands that trigger nuclear factor kappa B (NF-kappa B) DNA binding. High doses of IL-6 treatment remained without effect (Thibeault et al., 2001) . The early expression of IL-1 could activate the NF-B promoter to induce expression. The functional NF-B then binds the promoter of MIP-1 , and induces MIP-1 production. When IL-1 expression is blocked, MIP-1 expression is inhibited (Guo et al., 2004) .
The production of MCP-1 and MIP-1 could in turn elicit blood cell migration into the brain. In a stab wound model, MIP-1 induced T cell and neutrophil infiltration into the brain 3 days after surgery; monocytes/ macrophages were present in the injured area 12 days post injury (Ghirnikar et al., 1996) . In a human blood-brain-barrier model, MIP-1 expression increased shortly after amyloid-beta stimulation, and was followed by monocyte migration from the blood side to the brain side (Fiala et al., 1998) . Further, in MIP-1 knock out animals, there is a decrease in CD8 dendritic cell migration into the CNS after infection with mouse hepatitis virus (MHV) (Trifilo and Lane, 2004) . In addition, both MCP-1 and MIP-1 are involved in inflammatory cell recruitment in other tissues (Cook et al., 1995; Domachowske et al., 2000) after infection. MCP-1 and MIP-1 increase in hippocampus after entorhinodentate lesions prior to T cell and macrophage migration into the denervated hippocampus. When CCR2 (MCP-1 receptor) knockout animals were used, the cell migration was quenched, demonstrating a critical role for the CCR2 ligand MCP-1/CCL2 in leukocyte migration. Cellular infiltration was not altered by a mutation to CCR5 (a receptor of MIP-1 and RANTES/CCL5) (Che et al., 2001) . The deletion of MCP-1 may also result in upregulation of other cytokines (Ferreira et al., 2005) , suggesting a key role of MCP-1 in a cytokine network.
These findings suggested that MCP-1 and MIP-1 may be responsible for HUCB cell infiltration into the CNS after intravenous administration in stroke animals. However, it can be argued that a large enough difference in species homology could result in no HUCB response to rodent chemokine signals. This is unlikely since our interface migration system did induce HUCB migration, and exhibited a dose effect. This could be due to the conservation of both MCP-1 and MIP-1 ligands and their receptors across species (Nibbs et al., 1998; Rutledge et al., 1995) . In addition, we found constitutive expression of MCP-1 and MIP-1 receptors on HUCB.
In conclusion, we hypothesize that HUCB migration after ischemia begins with IL-1 secretion at the injury site, which initiates MCP-1 and MIP-1 secretion in activated astrocytes, microglia and some neurons. The accumulated MCP-1 and MIP-1 form a concentration gradient and when combined with the receptor at the surface of HUCB cells, induce migration of systemically administered HUCB cells. 
